Protein primary structure

The protein primary structure specifies the ordered amino acid residues of each polypeptide chain, joined through peptide bonds. A chain is conventionally written from its N-terminus to its C-terminus. In the broader chemical sense, a complete protein primary structure also specifies covalent bond crosslinks between chain positions, including protein disulfide bonds; a bare sequence string leaves that information unstated. This describes chemical connectivity rather than the spatial arrangement of protein tertiary structure or protein quaternary structure. See IUPAC Gold Book: primary structure, sequence and chain crosslinking and IUPAC-IUB, 3AA-16: writing residue sequences from the amino end. Some conventions reserve protein primary structure for sequence alone and call the complete chemical connectivity the covalent structure; the distinction should be stated when comparing descriptions. See IUPAC-IUB polypeptide-conformation recommendations, section 6.1: the narrower sequence-only convention.

In this toy example M denotes methionine, A alanine and G glycine. Both polypeptide chains have six amino acid residues, five peptide bonds, an M at the N-terminus and a G at the C-terminus. Their amino acid composition is identical, yet position 2 is A in MAGAMG and M in MMAAGG. There are $6!/(2!2!2!)=90$ distinct orders with these counts, a multinomial coefficient. Even fixing those two end residues leaves $4!/(1!2!1!)=12$ orders. The counts constrain the answer without determining it.

For multiple polypeptide chains, record each sequence separately and specify any protein disulfide bonds between cysteine positions. Mature insulin, for example, has an A chain of 21 amino acid residues and a B chain of 30 amino acid residues. Their combined 51 residues give $(21-1)+(30-1)=49$ peptide bonds, rather than the 50 of one unbroken 51-residue chain. See Cooper, The Cell: insulin's two chains and cysteine crosslinks, figure 2.16. A protein disulfide bond joins side groups; it does not concatenate the C-terminus of one chain with the N-terminus of another. The three insulin protein disulfide bonds connect A6 to A11 within the A chain, and A7 to B7 and A20 to B19 between chains. Positions are numbered from each chain's N-terminus. See Replacement of the interchain disulfide bridge-forming amino acids A7 and B7 by glutamate impairs the structure and activity of insulin: native disulfide positions.

Why keep this information? Protein primary structure lets us distinguish changes of chemical identity from changes of shape, and compare corresponding positions between proteins. Protein folding can bring distant amino acid residues together at a protein binding site while preserving their sequence. The attractive idea is that a readable linear record can constrain a complicated three-dimensional object; it is not, by itself, a guarantee of a unique fold in every environment. See protein folding and the ribonuclease A refolding experiment. Merely bending an intact chain preserves its protein primary structure; hydrolysis of a peptide bond, or changing which positions a protein disulfide bond connects, changes its chemical connectivity.

A protein sequence records the order of amino acid residues in a polypeptide chain. The sequence alone does not specify every modification, covalent crosslink, assembly state or conformation present in a purified sample.

For fixed length $n$ and the standard twenty-amino-acid alphabet, there are $20^n$ sequences: each position has twenty choices. This counts possible sequences, not stable protein folds; the sequence-to-structure relationship is many-to-one and some sequences do not form a stable folded protein.

The amino acid composition lists amounts or proportions of the different amino acid residues in a protein or specified polypeptide chain, without giving their order. The toy MAGAMG and MMAAGG each have counts M:2, A:2, G:2, or a proportion $1/3$ of each. Knowing composition therefore does not supply protein primary structure. Sanger's account begins by distinguishing the already available composition measurements from the largely unknown residue order. See Sanger's authored 1985 account of the move from composition to terminal-residue analysis.

Glycine is an amino acid, represented by Gly or G for an incorporated amino acid residue. Its amino acid side chain is a hydrogen chemical atom. It was identified at one insulin N-terminus in Sanger's insulin sequencing experiment. See IUPAC Blue Book, P-103.1: amino-acid names, symbols and structures.

Phenylalanine is an amino acid, represented by Phe or F for an incorporated amino acid residue. It was identified at the other insulin N-terminus in Sanger's insulin sequencing experiment. See IUPAC Blue Book, P-103.1: amino-acid names and symbols.

Cysteine is an amino acid whose amino acid side chain contains sulfur, represented by Cys or C for an incorporated amino acid residue. Two cysteine positions can be joined through a protein disulfide bond. See IUPAC Blue Book, P-103.1: cysteine's structure and symbols and Cooper: cysteine crosslinks in proteins. The C in a sequence means cysteine, whereas the C-end label in the toy diagram means C-terminus.

The motivating question was experimental: how could one recover the order in a protein when breaking all its peptide bonds destroys that order? Frederick Sanger and colleagues used complementary tests on portions of insulin. The following is an explanation of their evidence, not a laboratory recipe.

First, mark ends before destroying the chains. Sanger used the colored reagent fluorodinitrobenzene, abbreviated FDNB, to label free amino groups. After acid hydrolysis, the attached label remained on the end-residue products. Separating these derivatives by their different movement through solvents and comparing them with reference derivatives made the labels readable. The N-terminus products identified glycine and phenylalanine. Sanger emphasized that finding a stable label and a way to separate its products were both essential. See Sanger, Citation Classic (1985), discussing The free amino groups of insulin (1945). FDNB also labels suitable free amino groups on amino acid side chains, so a labeled product is not automatically an N-terminus product. See Sanger, The Chemistry of Insulin, Nobel lecture (1958), pp. 546–547.

Next, separate chains and preserve local order. Oxidation with performic acid broke the protein disulfide bonds, allowing A and B chains to be isolated. Partial hydrolysis and enzyme treatments produced fragments; these were separated and their composition and local sequences characterized. Overlaps between different fragment sets linked smaller sequences into longer ones. Many more fragments than minimally necessary were checked for consistency. See Sanger's authored Nobel lecture, pp. 547–552: chain separation, fragment analysis and sequence reconstruction.

The toy fragments make the logic visible. Suppose one cut pattern yields MAG and AMG, and another yields MA, GA and MG. The first set alone permits MAGAMG or AMGMAG. The fragment GA in the second set crosses the MAG–AMG boundary in MAGAMG; it does not occur in AMGMAG. Among concatenations of the first set, therefore, the second set selects MAGAMG. This example assumes intact, correctly identified fragments from one homogeneous chain and known fragment membership in each cut pattern. Repeated stretches, missing fragments or sample mixtures can leave ambiguities; the picture illustrates inference from overlaps, not a universal guarantee of reconstruction.

Finally, determine the protein disulfide bonds separately. Oxidation used to separate whole chains erases their original connections. Sanger and colleagues instead studied fragments still joined by protein disulfide bonds, then oxidized the isolated joined fragments to identify their component pieces and locate the connected chain regions. An important trap was rearrangement of disulfide bonds during treatment: products can acquire connections absent from the starting protein. Their work therefore had to establish conditions that prevented rearrangement before interpreting a linked fragment as evidence. See Ryle and Sanger, A Disulphide Interchange Reaction, Nature 171, 1025–1026 (1953) and Sanger's Nobel lecture, pp. 553–554: preserving and identifying disulfide connections. The result was an experimentally constrained chemical structure rather than a composition list or a photograph of a fold.

Insulin is a protein hormone. Its mature form has two polypeptide chains; identifying their sequences and protein disulfide bonds provided the motivating example in Sanger's insulin sequencing experiment. See Cooper: insulin as a two-chain hormone, figure 2.16.

A meal illustrates the insulin side of blood glucose homeostasis: rising glucose stimulates beta cells in the pancreatic islets, and released insulin favors uptake and storage of fuel. Alpha cells produce glucagon, while delta cells produce somatostatin, which inhibits release of both insulin and glucagon. The pancreas therefore contains interacting sensor and secretory biological cells, rather than one undifferentiated source of hormones. ^[ref]

Insulin and glucagon are peptide hormones, built from amino acid residues joined by peptide bonds; glucose is a small carbohydrate molecule. A hormone changes signal transduction, not the identity of the fuel it regulates. Human mature insulin has 51 amino acid residues in two polypeptide chains. Beta cells process proinsulin to insulin and C-peptide, storing the products in secretory granules for exocytosis. Increased glucose metabolism raises the ATP-to-ADP ratio, tending to close ATP-sensitive potassium channels; depolarization and entry of calcium ions then trigger exocytosis. This is an important triggering pathway, with additional amplification and modulatory inputs.^[ref]

Binding to the insulin receptor, a receptor tyrosine kinase, starts phosphorylation of the receptor and insulin receptor substrates. Recruitment of phosphoinositide 3-kinase and activation of Akt transmit a major metabolic branch. In skeletal muscle and adipose tissue, that branch helps move GLUT4 to the cell membrane, increasing glucose uptake by facilitated diffusion. GLUT4 is a membrane transport protein, not an insulin receptor. Insulin also favors glycogenesis in skeletal muscle and the liver, and inhibits lipolysis in adipose tissue. In the liver, suppression of glucose output involves enzyme regulation, gene expression, and indirect changes in substrate supply. Its relative direct and indirect contributions are more complex than a single Akt arrow. ^[ref]

Insulin is not a universal permission slip for glucose entry: red blood cells and much of the nervous system use uptake mechanisms that are not acutely dependent on insulin. Nor does the liver use the same GLUT4 switch as skeletal muscle. This is why reduced insulin action can change blood glucose dramatically without stopping all glucose uptake. ^[ref]

Diabetes can disrupt production, response, and counterregulation. Type 1 diabetes usually involves destruction of beta cells and severe loss of endogenous insulin; type 2 diabetes combines insulin resistance with insufficient beta cell compensation. High circulating insulin can therefore coexist with impaired insulin action. Inappropriate glucagon release can add to excessive liver glucose output, and the response to low blood glucose can also be impaired: "more glucagon" is not a complete description of diabetes. These distinctions explain mechanisms, rather than prescribe treatment. ^{[ref] [ref]}

A single polypeptide precursor whose processing yields mature insulin and C-peptide; it is not the two-chain mature hormone. The biosynthetic distinction is described under insulin.

Glucose clamp technique: a method for quantifying insulin secretion and resistance. by R. A. DeFronzo and others separates two questions. In a hyperglycemic clamp, variable glucose infusion holds blood glucose above baseline while sampled insulin reports the response. The 1979 article's abstract reports an early release burst followed by a slower rise. In a euglycemic insulin clamp, infused insulin is held elevated and variable glucose infusion holds blood glucose at baseline. Frequent blood sampling, a glucose analyzer, and controlled infusion apparatus make the imposed concentration a maintained condition rather than an uncontrolled consequence. ^[ref][ref]

The maintained glucose level controls an important confounder: a change in blood glucose would itself change uptake and hormone release. At a steady state, conservation of mass gives uptake equal to infused supply plus endogenous production, after accounting for losses. Consequently, infusion alone estimates uptake only if endogenous production is negligible and the other balance assumptions hold. Labelled glucose measurements can estimate residual endogenous production; matching infused insulin across comparisons matters. Whole-body uptake cannot by itself identify the responding tissue, and plasma insulin reflects both release and removal. This interpretation uses the accessible 1979 abstract and the later authored methods chapter; the original article's full methods were not available for inspection.^[ref]